Literature DB >> 18780231

Behavioral and neurophysiological hallmarks of simian immunodeficiency virus infection in macaque monkeys.

P D Cheney1, M Riazi, J M Marcario.   

Abstract

Macaque monkeys infected with various neurovirulent forms of simian immunodeficiency virus (SIV) represent highly effective models, not only of systemic acquired immunodeficiency virus (AIDS), but also neuroAIDS. Behavioral studies with this model have clearly established that SIV-infected monkeys show both cognitive and motor impairments resembling those that have been reported in human immunodeficiency virus (HIV)-infected humans. This paper combines data from a number of behavioral studies in SIV-infected macaque monkeys to obtain an overall estimate of the frequency of impairments in various motor and cognitive domains. The results were then compared to similar data from studies of HIV-infected humans. Whereas cognitive functions are most commonly impaired in HIV-infected humans, motor function is the domain most commonly impaired in SIV-infected monkeys. Electrophysiological studies in SIV-infected macaques have revealed deficits in motor-, somatosensory-, visual-, and auditory-evoked potentials that also resemble abnormalities in human HIV infection. Abnormalities in motor-evoked potentials were among the most common evoked potential deficits observed. Although differences in behavioral profiles of human HIV disease and SIV disease in monkeys exist, the results, nevertheless, provide strong validation for the use of macaque models for translational studies of the virology, immunology, pathophysiology, and treatment of neuroAIDS.

Entities:  

Mesh:

Year:  2008        PMID: 18780231     DOI: 10.1080/13550280802116322

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  48 in total

Review 1.  Paradigms for behavioral assessment of viral pathogenesis.

Authors:  M R Weed; L H Gold
Journal:  Adv Virus Res       Date:  2001       Impact factor: 9.937

2.  Abnormalities of central motor conduction in asymptomatic HIV-positive patients. Significance and prognostic value.

Authors:  C Zandrini; C Ciano; E Alfonsi; G Sandrini; L Minoli; A Moglia
Journal:  Acta Neurol (Napoli)       Date:  1990-08

3.  Neurotological auditory brain stem response findings in human immunodeficiency virus-positive patients without neurologic manifestations.

Authors:  E Castello; N Baroni; E Pallestrini
Journal:  Ann Otol Rhinol Laryngol       Date:  1998-12       Impact factor: 1.547

4.  Impaired performance on the object retrieval-detour test of executive function in the SIV/macaque model of AIDS.

Authors:  Rachel A Gray; Kristin M Wilcox; M Christine Zink; Michael R Weed
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

5.  Motor analysis predicts progression in HIV-associated brain disease.

Authors:  G Arendt; H Hefter; F Hilperath; H J von Giesen; G Strohmeyer; H J Freund
Journal:  J Neurol Sci       Date:  1994-05       Impact factor: 3.181

Review 6.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

7.  The HIV Dementia Scale: predictive power in mild dementia and HAART.

Authors:  Kara Anne Bottiggi; Jason J Chang; Frederick A Schmitt; Malcolm J Avison; Yunanan Mootoor; Avindra Nath; Joseph R Berger
Journal:  J Neurol Sci       Date:  2007-05-04       Impact factor: 3.181

8.  Impaired performance on a rhesus monkey neuropsychological testing battery following simian immunodeficiency virus infection.

Authors:  Michael R Weed; Lisa H Gold; Ilham Polis; George F Koob; Howard S Fox; Michael A Taffe
Journal:  AIDS Res Hum Retroviruses       Date:  2004-01       Impact factor: 2.205

9.  Multimodal evoked potentials in HIV infected patients.

Authors:  G Farnarier; H Somma-Mauvais
Journal:  Electroencephalogr Clin Neurophysiol Suppl       Date:  1990

10.  Longitudinal analysis of behavioral, neurophysiological, viral and immunological effects of SIV infection in rhesus monkeys.

Authors:  L H Gold; H S Fox; S J Henriksen; M J Buchmeier; M R Weed; M A Taffe; S Huitrón-Resendiz; T F Horn; F E Bloom
Journal:  J Med Primatol       Date:  1998 Apr-Jun       Impact factor: 0.667

View more
  5 in total

1.  Functional brain abnormalities during finger-tapping in HIV-infected older adults: a magnetoencephalography study.

Authors:  Tony W Wilson; Elizabeth Heinrichs-Graham; Kevin R Robertson; Uriel Sandkovsky; Jennifer O'Neill; Nichole L Knott; Howard S Fox; Susan Swindells
Journal:  J Neuroimmune Pharmacol       Date:  2013-06-09       Impact factor: 4.147

Review 2.  Behavioral, Metabolic, and Immune Consequences of Chronic Alcohol or Cannabinoids on HIV/AIDs: Studies in the Non-Human Primate SIV Model.

Authors:  Patricia E Molina; Angela M Amedee; Peter Winsauer; Steve Nelson; Gregory Bagby; Liz Simon
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-21       Impact factor: 4.147

3.  Tolerance to chronic delta-9-tetrahydrocannabinol (Δ⁹-THC) in rhesus macaques infected with simian immunodeficiency virus.

Authors:  Peter J Winsauer; Patricia E Molina; Angela M Amedee; Catalin M Filipeanu; Robin R McGoey; Dana A Troxclair; Edith M Walker; Leslie L Birke; Curtis Vande Stouwe; Jessica M Howard; Stuart T Leonard; Joseph M Moerschbaecher; Peter B Lewis
Journal:  Exp Clin Psychopharmacol       Date:  2011-04       Impact factor: 3.157

4.  Effects of Morphine on Behavioral Task Performance in SIV-Infected Rhesus Macaques.

Authors:  Joanne K Marcario; Gurudutt Pendyala; Mariam Riazi; Kandace Fleming; Janet Marquis; Shannon Callen; Steven J Lisco; Stephen C Fowler; Paul D Cheney; Shilpa J Buch
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-02       Impact factor: 4.147

5.  Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy.

Authors:  Christian Wächter; Lee E Eiden; Nedye Naumann; Candan Depboylu; Eberhard Weihe
Journal:  J Neuroinflammation       Date:  2016-10-14       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.